Cryptococcosis

Slide 1 · Cryptococcosis

Infectious disease pathology | Organism, virulence, tissue response, and CNS disease

Encapsulated yeasts

Host response

Diagnostic morphology

Clinicopathologic correlation

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

Distinguish the disease profiles of C. Neoformans and C. Gattii.

Explain how capsule, melanin, enzymes, and cell-wall biology influence infection.

Recognize pulmonary, CNS, and disseminated patterns of cryptococcosis.

Link host immune status to histologic inflammation and diagnosis.

Slide 3 · Where cryptococcosis fits among mycoses

Fungal disease

Mycosis = infection produced by a fungus

Growth form

Cryptococcus: An encapsulated budding yeast in human tissue

Disease category

Often opportunistic; Also occurs without recognized immunodeficiency

Organ emphasis

Pulmonary entry; Characteristic major lesions in the CNS

Slide 4 · Yeast morphology is the starting point

Yeast biology

Cryptococcus in human tissue

Single-cell growth

Rounded to oval yeast forms

Budding

Yeasts reproduce by budding

Hyphae / pseudohyphae

Neither form in human hosts

Diagnostic implication

Search for encapsulated yeast, not filamentous fungi

Slide 5 · Two human pathogens in the source

C. Neoformans

C. Gattii

Commonly opportunistic

Can affect immunocompetent hosts

Pigeon-guano–associated soil

Trees and soil reservoirs

Major CNS infection

May form bulky pulmonary or CNS lesions

Occurs worldwide

Reported in several temperate and tropical regions

Slide 6 · Inhalation links environment to host

Environmental reservoir

Soil or arboreal sources

Acquisition

Inhalation of fungal material

Primary infection

Lung is the initial site

Potential consequences

CNS infection ± dissemination

Slide 7 · The lung can conceal early infection

The pulmonary portal of entry is established in the source.

Pulmonary disease is often mild or clinically asymptomatic.

Important CNS involvement may arise despite modest lung symptoms.

Therefore pulmonary symptom burden need not indicate organism burden elsewhere.

Slide 8 · C. Neoformans: Predisposing conditions

Acquired immunodeficiency

AIDS

Hematologic disorders

Leukemia and lymphoma

Immune-mediated diseases

Systemic lupus erythematosus and sarcoidosis

Therapy-related suppression

Transplant immunosuppression; High-dose corticosteroids

Slide 9 · High-dose corticosteroids matter

At-risk host

High-dose corticosteroid exposure

Host setting

Immunosuppression

Pathogen

C. Neoformans infection

Outcome spectrum

Meningoencephalitis or disseminated disease

Slide 10 · Cryptococcosis is not exclusively opportunistic

Immunosuppressed host

Apparently immunocompetent host

High susceptibility to C. Neoformans

C. Neoformans disease is still possible

May have few inflammatory cells

Granulomatous response may predominate

Wide dissemination may occur

C. Gattii disease warrants immune evaluation

Subtle inflammatory histology

Large mass-like lesions may occur

Slide 11 · Historical global burden in HIV

152,000

Estimated cryptococcal meningitis cases

112,000

Associated deaths

19%

AIDS-related mortality attributed

All figures are Robbins-reported 2020 worldwide estimates in HIV-infected people; Not current surveillance.

Slide 12 · C. Neoformans: Ecological exposure

Environmental source

Found in soil, notably where pigeon guano accumulates.

Exposure occurs by inhalation.

Environmental exposure does not establish clinical disease.

Schematic exposure model; No quantitative dose–response asserted.

Slide 13 · C. Gattii: Arboreal reservoirs

Tree associations

Oak, baobab, and especially eucalyptus

Additional niche

Also identified in soil

Route of acquisition

Inhalation

Clinical teaching point

Environmental setting can differ from C. Neoformans

Slide 14 · C. Gattii: Geographic range

Historically considered a tropical or subtropical pathogen.

Now reported in Australia and British Columbia / other Canadian regions.

Additional reports include the U.S. Pacific Northwest, South America, and Africa.

C. Gattii as responsible for 11%–33% of global infections.

Slide 15 · C. Gattii: Why evaluate immunity?

Recognized disease

C. Gattii identified

Host assumption

May appear immunocompetent

Important caveat

Possible immune/genetic predisposition

Actionable correlation

Evaluate immune function

Slide 16 · C. Gattii can simulate a tumor

Pulmonary lesion

CNS lesion

Solitary circumscribed granuloma

Large cryptococcoma / mass

May resemble a coin lesion

May cause pressure and mass effects

Can resemble histoplasmosis

May resemble neoplasm on imaging

Evaluate tissue and organism

Do not infer diagnosis from imaging alone

Slide 17 · Virulence factors: Organizing framework

Surface structures

Polysaccharide capsule; Chitin cell wall

Cell adaptation

Titan cells and small microcells

Biochemical defenses

Melanin generated by laccase

Enzymes / secreted proteins

Phospholipases, urease, CPL1

Slide 18 · The polysaccharide capsule

Capsule

Yeast cell

Cell wall

Schematic — proportions and cell shape are illustrative, not microscopy.

Slide 19 · GXM interferes with phagocytosis

Capsular GXM

Antiphagocytic surface

Innate-cell effect

Reduced uptake by alveolar macrophages

Tissue consequence

Reduced early clearance

Pathogen advantage

Improved persistence

Slide 20 · Capsule affects leukocyte recruitment

Capsular polysaccharide

GXM

Cell recruitment

Leukocyte migration is inhibited

Inflammatory response

Reduced recruitment to the lesion

Morphology link

Potential paucity of inflammation

Slide 21 · Dendritic-cell antigen presentation

Cryptococcus

Host defense modulation

Dendritic cells

Reduced MHC II–dependent presentation

Cytokine production

IL-12 and IL-23 inhibited

Immune consequence

Antifungal response may be blunted

Slide 22 · IL-12 and IL-23 are suppressed

The source links cryptococcal infection to inhibition of dendritic-cell IL-12 production.

IL-23 production is also reduced.

The same passage identifies reduced MHC class II antigen presentation.

These are experimentally described immune-evasion effects, not a clinical cytokine panel.

Slide 23 · Titan cells: Unusually large yeasts

Typical yeast

5–10 μm

Titan cell

10–100 μm

Thick cell wall

One of several cell-size forms

Schematic — relative diameters do not depict exact size scaling.

Slide 24 · Microcells: Very small fungal forms

Microcells: 2–4 μm

May be adapted for growth in macrophages

Host-cell schematic; This relationship is proposed, not established in the excerpt.

Schematic macrophage containing small yeast forms; Not a photomicrograph.

Slide 25 · Size heterogeneity complicates recognition

Cryptococcal form

Textbook-reported size

Microcell

2–4 μm

Typical yeast

5–10 μm

Titan cell

10–100 μm

Interpretation

Compare morphology with capsule and clinical context

Slide 26 · Melanin synthesis depends on laccase

Yeast enzyme

Laccase

Biochemical product

Melanin

Surface function

Antioxidant properties

Biological advantage

Protection against host stress

Slide 27 · Melanin: Multiple protective roles

Oxidative stress

Antioxidant activity

Antibody defense

Decreases antibody-mediated phagocytosis

Antifungal exposure

Counteracts antifungal-agent effects

Cell biology

Binds iron and provides wall integrity

Slide 28 · Melanin and the phagocyte encounter

Host defensive pressure

Melanin-associated countermeasure

Oxidant-mediated attack

Antioxidant properties

Antibody-mediated uptake

Reduced phagocytosis

Chemical stress from treatment

Interference with antifungal effects

Cell wall stress

Support of structural integrity

Slide 29 · Phospholipases may aid invasion

Secreted activity

Fungal phospholipases

Substrate effect

Degradation of cell-wall components

Potential role

Support of tissue invasion

Evidence framing

“May aid” in the source

Slide 30 · Urease modifies phagocytic conditions

Fungal enzyme

Urease

Local chemistry

Counteracts reactive oxygen species and pH

Host compartment

Phagocytic cell

Pathogen advantage

Greater tolerance of microbicidal conditions

Slide 31 · Chitin maintains wall stability

Structural component

Chitin

Fungal cell wall

Mechanical stabilization

Genetic disruption

Chitin mutants

Observed implication

Reduced virulence

Slide 32 · CPL1: A secreted immune modulator

CPL1 is a cysteine-rich secreted cryptococcal protein.

The Robbins passage associates CPL1 with macrophage activation.

Macrophage activation should not automatically be labeled immunosuppression.

Distinguish this described function from the antiphagocytic effect of capsule.

Slide 33 · Virulence acts through distinct routes

Escape uptake

Capsule, GXM; Melanin

Modify host signaling

Dendritic-cell pathways; CPL1

Tolerate damage

Melanin; Urease; Chitin-dependent wall

Interact with tissue

Phospholipases and organism morphology

Slide 34 · Primary lung infection to major CNS disease

Inhalation

Environmental fungus

Lung

Often mild or silent infection

Possible spread

Extrapulmonary involvement

CNS

Meninges and brain tissue

Slide 35 · Pulmonary cryptococcosis: Pathology

The lung is the primary portal of infection.

Visible or clinically obvious lung disease may be limited.

C. Gattii may produce a solitary pulmonary granuloma.

A focal lesion can be radiologically similar to a “coin” lesion.

Slide 36 · Pulmonary coin lesions require context

Cryptococcal possibility

Diagnostic interpretation

C. Gattii granuloma

An infectious cause of a solitary nodule

Circumscribed lung focus

Can resemble a Histoplasma-associated lesion

Imaging appearance

Morphology alone may not define species

Tissue assessment

Search for encapsulated yeast if infection suspected

Slide 37 · The diagnostic organism is a yeast

Gelatinous capsule

Budding yeast

No hyphal forms

Schematic — proportions and cell shape are illustrative, not microscopy.

Slide 38 · Capsular histochemistry

Periodic acid–Schiff (PAS)

Mucicarmine

Capsular material stains intense red

Capsule stains intense red

Shows polysaccharide-rich fungal structures

Especially emphasizes gelatinous capsule

Part of histologic recognition

Robbins Figure 8.44 uses this stain

Interpret with tissue morphology

Interpret with tissue morphology

Slide 39 · What mucicarmine demonstrates

Red-staining capsular polysaccharide

Mucicarmine / PAS (as)

Yeast-shaped organism with thick capsule

Schematic teaching illustration; Not a stained tissue section.

Slide 40 · Cryptococcal antigen detection

Encapsulated yeast

Polysaccharide-containing capsule

Released/available material

Cryptococcal antigen

Clinical specimen

Blood or CSF

Detection

Immunoassays

Slide 41 · Histology and antigen tests answer different questions

Tissue morphology

Fluid antigen assay

Visualizes organism and tissue response

Detects cryptococcal polysaccharide antigen

Allows localization in lesions

May support infection in blood or CSF

Stains include PAS / mucicarmine

Immunoassay is not an image of fungal cells

Shows inflammation and distribution

Does not directly document tissue architecture

Slide 42 · Major CNS anatomic sites

Meninges

Cortical gray matter

Basal nuclei

Anatomic schematic — relative dimensions and boundaries are not imaging anatomy.

Slide 43 · Meningeal involvement

Cryptococcal infection can involve the meningeal surfaces.

In immunosuppressed people, abundant organisms may collect as gelatinous masses.

Inflammatory reaction may be minimal despite the organism burden.

Clinical presentations include meningitis and meningoencephalitis.

Slide 44 · Virchow–Robin spaces are a key compartment

Blood vessel

Yeasts expand surrounding perivascular space

Simplified schematic of Virchow–Robin space expansion; Not a brain histologic section.

Slide 45 · Soap-bubble lesions: Mechanism

Perivascular space

Virchow–Robin compartment

Fungal expansion

Yeasts accumulate

Tissue architecture

Perivascular space dilates

Pathologic appearance

Soap-bubble change

Slide 46 · A large fungal burden can elicit little response

Abundant cryptococci

Weak host inflammatory reaction

Gelatinous aggregates

Few inflammatory cells

Meningeal masses

Limited meningeal cellular response

Dilated perivascular spaces

Minimal gliosis may be present

Severe disease

Inflammatory appearance can be deceptively mild

Slide 47 · Disseminated disease in immunosuppression

Cutaneous

Skin

Reticuloendothelial

Liver and spleen

Endocrine

Adrenal glands

Musculoskeletal

Bones

Slide 48 · Granulomas reflect a different host response

More effective or prolonged response

Host immunocompetence / chronicity

Recruitment

Macrophages + lymphocytes

Giant-cell reaction

Foreign body–type giant cells

Tissue pattern

Chronic granulomatous inflammation

Slide 49 · Cells in cryptococcal granulomas

Macrophages

Predominant mononuclear phagocytes

Lymphocytes

Chronic inflammatory infiltrate

Giant cells

Foreign body–type multinucleated cells

Organisms

Yeasts within or around granulomatous reaction

Slide 50 · Other CNS inflammatory patterns

Suppurative inflammation may occur.

Granulomatous arteritis may involve the circle of Willis.

The tissue reaction is therefore not invariably gelatinous or noninflammatory.

A pattern should be interpreted in the context of immune status and duration.

Slide 51 · Immune status changes histopathology

Marked immunosuppression

Immunocompetence / prolonged disease

Many yeasts, limited inflammation

Granulomatous inflammation

Gelatinous meningeal collections

Macrophages and lymphocytes

Virchow–Robin enlargement

Foreign body–type giant cells

Potential dissemination

Other reactions may include suppuration

Slide 52 · Cryptococcal meningitis: Clinical tempo

Rapid course

Indolent course

May be fulminant

May evolve over months or years

Can be fatal within approximately 2 weeks

Course may remain prolonged

Recognized in AIDS and other immunosuppression

Also occurs outside severe immunosuppression

Tempo does not replace organism testing

Tempo does not replace organism testing

Slide 53 · CSF findings may understate inflammation

CSF can contain few cells despite cryptococcal meningitis.

Protein concentration is usually increased CNS discussion.

Encapsulated yeasts may be identified with special stains.

Cryptococcal antigen assays offer a separate diagnostic route.

Slide 54 · Cryptococcomas can generate mass effect

C. Gattii CNS infection

Can form a focal mass

Local anatomy

Space-occupying lesion

Physiologic consequence

Increased CNS pressure

Radiologic pitfall

May resemble neoplasm

Slide 55 · Cryptococcus versus Candida in the CNS

Cryptococcus

Candida

Often expanded perivascular spaces

Often multiple cerebral microabscesses

Yeast aggregates may evoke little gliosis

Suppurative foci may predominate

Meningitis may be prominent

Microabscesses ± granulomas

Capsulated yeasts

Budding yeasts and pseudohyphae in candidiasis

Slide 56 · Diagnostic synthesis: Choose the right sample

Clinical suspicion

CNS / lung / disseminated infection

Sample / tissue

CSF, blood or tissue when indicated

Detection approach

Cryptococcal antigen or microscopy

Interpretation

Morphology + host context

Slide 57 · Diagnostic pitfalls to avoid

Pitfall 1

Minimal inflammation does not exclude severe infection

Pitfall 2

A solitary nodule may be fungal rather than neoplastic

Pitfall 3

No hyphae is expected in tissue cryptococcosis

Pitfall 4

Organism size varies across microcells, typical yeasts, and Titan cells

Slide 58 · Case: Advanced AIDS and meningeal disease

A patient with advanced AIDS develops meningoencephalitis. CSF contains relatively few cells despite severe illness.

Reason through the findings

Which fungal disease is strongly suggested?

Why might the cellular response be scant?

Which source-supported assay could aid diagnosis?

Suggested answer and teaching rationale are available in presenter notes.

Slide 59 · Case: A pulmonary coin lesion

An adult with a solitary pulmonary nodule has a tissue granuloma. An encapsulated yeast is identified.

Reason through the findings

Which cryptococcal species is especially associated with a solitary pulmonary granuloma?

What other fungal infection is specifically compared?

Why is imaging alone insufficient?

Suggested answer and teaching rationale are available in presenter notes.

Slide 60 · Case: CNS mass without known immunodeficiency

A patient thought immunocompetent has a focal CNS lesion resembling a tumor. Tissue shows cryptococcal infection.

Reason through the findings

Which species deserves particular attention?

What is the reason for pressure-related symptoms?

What aspect of the host requires assessment?

Suggested answer and teaching rationale are available in presenter notes.

Slide 61 · Case: Interpreting a red capsular stain

A pathology section shows rounded budding fungi with intense red capsular material on mucicarmine.

Reason through the findings

What key organism feature is highlighted?

What tissue growth form is expected?

Which two compartments frequently show major lesions?

Suggested answer and teaching rationale are available in presenter notes.

Slide 62 · Morphology and biology: Integrate the evidence

Encapsulated yeast

Capsule contributes to evasion + stains with mucicarmine/PAS

Sparse inflammation

Consistent with immune impairment / reduced recruitment

Soap-bubble spaces

Organisms distend cerebral perivascular spaces

Granulomas / giant cells

Reflect sustained host response

Slide 63 · Five mechanistic conclusions

Inhalation produces a pulmonary portal, but the CNS may dominate disease.

Capsule and host-signaling effects attenuate early antifungal defenses.

Melanin, chitin, and enzymes support fungal survival and pathogenicity.

Host immune function strongly influences the histologic pattern.

Correct diagnosis integrates fungal morphology, specimen findings, and clinical setting.

Slide 64 · Selected references

Robbins, Cotran & Kumar. Pathologic Basis of Disease. 11th ed. Infectious Diseases: fungal infections and cryptococcosis.

Robbins, Cotran & Kumar. Pathologic Basis of Disease. 11th ed. The Central Nervous System: fungal infections.